Ocugen, Inc. announced today that it has entered into a securities purchase agreement with Janus Henderson Investors for a registered direct offering totaling $20 million. The offering includes the purchase of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock. The purchase price for each share and accompanying warrant is $1.00, based on the closing price on August 7, 2025.
The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. These warrants are callable by the company if the volume-weighted average price (VWAP) of Ocugen’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. Noble Capital Markets, Inc. acted as the sole placement agent for this offering.
The gross proceeds to Ocugen are expected to be approximately $20 million before deducting fees and estimated offering expenses. The company may receive up to an additional $30 million in gross proceeds if the warrants are exercised in full. The offering is anticipated to close on or about August 11, 2025, subject to customary closing conditions. This capital infusion is crucial for funding ongoing operations and clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.